Fundraising Fox

Audentes Therapeutics

San Francisco, US · Founded 2012 · Delaware corporation · 6 known investors

astellasgenetherapies.com ↗
Biotech

Founders & leadership

Audentes Therapeutics was founded in 2012 by Matthew Patterson.

MP
Matthew PattersonFounder
JS
Jonathan SIlversteinNamed on SEC filing

Board

JSJonathan Silverstein
Jonathan SilversteininBoard directorPartner at OrbiMed
SSSteve Squinto
Steve SquintoinBoard directorVenture Partner at OrbiMed
KP
Kush ParmarBoard director
JL
Jonathan LeffBoard directorPartner at Deerfield Management Company
TW
Thomas WoiwodeBoard director
LG
Louis G. LangeBoard directorPartner at Asset Management Company
TS
Thomas SchuetzBoard director

Investors · 6

Asset Management CompanyMenlo Park · $500K – $2M
RA CapitalBoston
venBio PartnersSan Francisco
Deerfield Management CompanyreportedNew Yorkvia Jonathan Leff · board
OrbiMedreportedNew York · $1M – $75Mvia Jonathan Silverstein · board
VenrockreportedPalo Alto · $500K – $10M

Reported raises · per SEC filings

Form D private placements

$107.5M disclosed across 2 of 3 rounds · 2014–2015

▶$65MraisedOct 2015 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steve SquintoDirector
  • Matthew PattersonExecutive Officer, Director
  • Jonathan LeffDirector
  • Kush ParmarDirector
  • Thomas WoiwodeDirector
  • Jonathan SilversteinDirector
  • Thomas SchuetzDirector
  • Louis LangeDirector
Offering amount
$65M
Amount sold
$65M
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedSep 2015 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan SilversteinDirector
  • Steve SquintoDirector
  • Kush ParmarDirector
  • Jonathan LeffDirector
  • Matthew PattersonExecutive Officer, Director
  • Thomas WoiwodeDirector
  • Louis G. LangeDirector
  • Thomas SchuetzDirector
First sale
Aug 2015
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42.5MraisedDec 2014 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas SchuetzDirector
  • Kush ParmarDirector
  • Matthew PattersonExecutive Officer, Director
  • Jonathan SIlversteinDirector
  • Thomas WoiwodeDirector
  • Jonathan LeffDirector
Offering amount
$42.5M
Amount sold
$42.5M
First sale
Nov 2014
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Audentes Therapeutics went on to found or lead other companies.

Kush M ParmarBoard Of DirectorsFounded Homology Medicines, Inc.Lou LangeDirectorFounded CV Therapeutics

In the news

Audentes Therapeutics | San Francisco other | Altssaltss.com · Jun 2026TMRW Life Sciences Raises $25 Million In Series B Funding Led By 5AM Venturesprnewswire.com · Dec 2019San Francisco's Audentes Therapeutics Rakes In $42.5 Million Series B - BioSpacebiospace.com · Dec 2014Audentes Therapeutics Raises $42.5 Million in Series B Financing | Fierce Biotechfiercebiotech.com · Dec 2014

Frequently asked questions

Who founded Audentes Therapeutics?
Audentes Therapeutics was founded by Matthew Patterson in 2012.
Who are Audentes Therapeutics's investors?
Audentes Therapeutics's investors include Asset Management Company, RA Capital, venBio Partners, Deerfield Management Company, OrbiMed, Venrock.
How much funding has Audentes Therapeutics raised?
Audentes Therapeutics has disclosed $107.5M raised across 2 of its 3 known rounds.
Where is Audentes Therapeutics headquartered?
Audentes Therapeutics is headquartered in San Francisco, US.